Prevalence, Severity, Risk Factors, and Prognostic Value of Hyponatremia in Patients With Traumatic Brain Injury (WATERWAR)
Prevalence, Severity, Risk Factors, and Prognostic Value of Hyponatremia in Patients With Traumatic Brain Injury : a Retrospective Cohort Study.
Hyponatremia (HN) is the most common electrolytic disorder in the traumatic brain injury (TBI) population, found in 17 to 51% of patients according to the series. Two etiologies predominate in the literature, the Syndrome of Inappropriate Anti Diuretic Hormone (SIADH) and the Cerebral Salt Waste Syndrome (CSW), but none has been precisely described in terms of epidemiology, risk factors or severity. Moreover, SIADH and CSH were often confused in previous works.
The main goal of our study is to assess retrospectively prevalence, severity, time to onset, length, risk factors of HN in a large population of TBI patients, as well as treatment modalities and prognosis. A specific distinction was performed between SIADH or CSW.
研究概览
地位
条件
详细说明
This is a retrospective descriptive study.
The included patients will be those admitted in the trauma intensive care unit of Lapeyronie University Hospital (Montpellier, France) with a TBI (head AIS ≥1) during a period of 4 years, 01/01/2014 to 31/12/2017.
Using our databank the investigators estimate 650 to 700 patients who met inclusion criteria during this period and will be analyzed. Inclusions will be confirmed after the opening of medical records.
Definition of SIADH is defined as the occurrence of a hyponatremia (≤135 mmol/L) associated with inappropriate urine concentration (urinary/plasmatic osmolarity ≥1) and a low daily urine volume (<1500 ml/24H).
Definition of CSW is defined as the occurrence of a hyponatremia (≤135 mmol/L) associated with a massive natriuresis (>140 mmol/L) and a daily urine volume > 1500 ml/24H.
Data collection will concern the medical records: medical history, traumatism severity, cerebral injuries on computed tomography, severe complications, specific treatments, and biological course from ICU admission to discharge.
The main endpoint will be the prevalence of hyponatremia (≤135 mmol/L) in the first 10 days after the traumatic brain injury.
The secondary endpoints will be the prevalence specific prevalence of CSW and SIADH, risk factors of these nosological entities, their severity, their timing to onset and their morbimorality.
研究类型
注册 (预期的)
联系人和位置
学习联系方式
- 姓名:Jonathan CHARBIT, MD
- 电话号码:33 467338256
- 邮箱:j-charbit@chu-montpellier.fr
学习地点
-
-
Montepllier
-
Montpellier、Montepllier、法国、34295
- 招聘中
- Uhmontpellier
-
接触:
- Jonathan CHARBIT, MD
- 电话号码:33 467338256
- 邮箱:j-charbit@chu-montpellier.fr
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion criteria:
- âge ≥ 18 years
- presence of traumatic brain injury at the ICU admission
Exclusion criteria:
- Discharged from ICU or death < 48 hours from the admission
- Lack of data
学习计划
研究是如何设计的?
设计细节
- 观测模型:队列
- 时间观点:追溯
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Occurrence of hyponatremia
大体时间:during the 10 first days after the traumatic brain injury
|
Hyponatremia ≤ 135mmol/L
|
during the 10 first days after the traumatic brain injury
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Occurrence SIADH
大体时间:during the 10 first days after the traumatic brain injury
|
Hyponatremia ≤ 135mmol/L associated with inappropriate urine concentration (urinary/plasmatic osmolarity ≥1) and a low daily urine volume (<1500 ml/24H).
|
during the 10 first days after the traumatic brain injury
|
|
Occurrence CSW
大体时间:during the 10 first days after the traumatic brain injury
|
Hyponatremia (≤135 mmol/L) associated with a massive natriuresis (>140 mmol/L) and a daily urine volume > 1500 ml/24H
|
during the 10 first days after the traumatic brain injury
|
|
Determination of risk factors of hyponatremia
大体时间:during the 10 first days after the traumatic brain injury
|
Traumatics injuries, early management, early complications, sodium and water intakes, treatments.
|
during the 10 first days after the traumatic brain injury
|
|
Morbi-mortality
大体时间:Day 1 (Hospitalization)
|
Death, duration of mechanical ventilation, duration of renal replacement therapy, length of ICU stay and length of hospitalization.
|
Day 1 (Hospitalization)
|
合作者和调查者
调查人员
- 首席研究员:Jonathan CHARBIT, MD、University Hospital, Montpellier
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- RECHMPL22_0011
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.